ABDO has welcomed the approval by the Medicines and Healthcare products Regulatory Agency (MHRA) of Ryjunea (low-dose atropine 0.1mg/ml), the first licensed low-dose atropine (LDA) eye drop in the UK for slowing the progression of childhood myopia.
Licensed by Santen, Ryjunea is indicated for children aged three to 14 years with myopia between -0.50DS and -6.00DS, and a progression rate of 0.50DS or more per year.
The product will be available initially for private prescribing. NICE is awaiting ministerial approval to begin a technology appraisal, after which access pathways may be reviewed.
Research cited by Santen shows that childhood myopia rates in the UK have more than doubled over the past 50 years, driven by lifestyle factors such as increased screen time and reduced time outdoors.
The availability of a licensed LDA treatment is thought to represent an important step forward in supporting eyecare professionals to manage this growing public health concern.
“We welcome MHRA approval of a licensed low-dose atropine product for myopia management,” said Max Halford, ABDO clinical and policy director. “This marks a significant milestone for the profession, providing a new therapeutic option to consider when discussing myopia control strategies with children and their families.
“Dispensing opticians involved in myopia management must continue to work closely with optometrists and ophthalmologists, ensuring that care is delivered safely, collaboratively, and always in the best interests of the patient,” added Max.
Neil Parkin, Santen general manager for the UK and Ireland, commented: “The UK approval is an important milestone in improving awareness and access to care for children with short-sightedness. We want to help shift the conversation from correction to control, supporting clinicians, schools, and parents to take early action.”